MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS
NASDAQ
US Flag
MREO

MREO
MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS
US Flag
NASDAQ
 
Prev
Open
Volume
 — 
Day's Range
Prev
Open
Volume
 — 
Day's Range

MREO Stock Chart

Financials

Valuation
Enterprise Value/EBITDA, TTM
Enterprise Value, FQ
Market Cap — Basic
Number of Employees
Number of Shareholders
Price/Earnings, TTM
Price/Revenue, TTM
Price/Book Ratio, FY
Price/Sales Ratio, FY
Balance Sheet
Current Ratio, FQ
Debt to Equity, FQ
Net Debt, FQ
Quick Ratio, FQ
Total Assets, FQ
Total Debt, FQ
Operating Metrics
Return on Assets, TTM
Return on Equity, TTM
Return on Invested Capital, TTM
Revenue per Employee, TTM
Price History
Average Volume (10 day)
Beta - 1 Year
Price - 52 Week High
Price - 52 Week Low
Dividends
Dividends Paid, FY
Dividends per Share, FY
Expected Annual Dividends
Dividends Yield
Margins
Net Margin, TTM
Gross Margin, TTM
Operating Margin, TTM
Pretax Margin, TTM
Income Statement
Basic EPS, Net Income
Earnings per Share, Basic, TTM
EBITDA, TTM
Gross Profit, FY
Last Annual EPS
Last Annual Revenue, FY
Net Income, FY
Total Revenue, FY
Free Cash Flow, TTM

Profile

Sector: Healthcare
Industry: Biotechnology & Medical Research
Employees: 31
Mereo BioPharma Group PLC is a United Kingdom-based biopharmaceutical company. The Company is focused on development and commercialization of therapeutics for patients with rare diseases. Its pipeline includes BPS-804, MPH-966, BCT-197, BGS-649, Navicixizumab and Etigilimab. BPS-804 (setrusumab) is being developed to improve bone strength and thereby reduce fractures in the orphan disease osteogenesis imperfecta (OI). MPH-966 (alvelestat) is being developed for alpha-1 antitrypsin deficiency (AATD). BGS-649 (leflutrozole) is being developed for the treatment of obese men with hypogonadotropic hypogonadism (HH). BCT-197 (acumapimod) is being developed as a therapy for acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Navicixizumab is being developed for platinum-resistant ovarian cancer. Etigilimab is being developed for advanced or metastatic solid tumors.

News

Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing House Rules Moderators Website & Broker Solutions Widgets Charting Solutions Get Help Feature Request Blog & News FAQ Wiki Twitter
Profile Profile Settings Account and Billing Get Help Ideas Published Followers Following Private Messages Chat Sign Out